Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003145057 | SCV003831056 | uncertain significance | Intellectual disability, X-linked, syndromic, Houge type | 2022-03-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004614408 | SCV005109369 | uncertain significance | Inborn genetic diseases | 2024-05-08 | criteria provided, single submitter | clinical testing | The c.3010A>G (p.T1004A) alteration is located in exon 22 (coding exon 22) of the CNKSR2 gene. This alteration results from a A to G substitution at nucleotide position 3010, causing the threonine (T) at amino acid position 1004 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003946451 | SCV004762826 | uncertain significance | CNKSR2-related disorder | 2023-12-13 | no assertion criteria provided | clinical testing | The CNKSR2 c.3010A>G variant is predicted to result in the amino acid substitution p.Thr1004Ala. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. This alteration is in the terminal exon, and no other variants nearby have been reported as causative. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |